title: Optimization of Time Controlled 6-mercaptopurine Delivery for Site- Specific Targeting to Colon Diseases.
abstract: BACKGROUND
  6-MP has short elimination time (<2 h) and low bioavailability (~ 50%). Present study was aimed to develop time controlled and site targeted delivery of 6-Mercaptopurine (6-MP) for treatment of colon diseases.
  
  
  METHODS
  Compression coating technique was used. 32 full factorial design was designed for optimization of the outer coat for the core tablet. For outer coat amount of Eudragit RS 100 and hydroxypropyl methylcellulose (HPMC K100) were employed as independent variables each at three levels while responses evaluated were swelling index and bursting time. Direct compression method was used for tablets formulation.
  
  
  RESULTS
  80% w/w of microcrystalline cellulose and 20% w/w of croscarmellose sodium were found to be optimum concentration for the core tablet. The outer coat of optimized batch (ED) contains 21.05% w/w Eudragit RS 100 and 78.95% w/w HPMC K100 of total polymer weight. In-vitro dissolution study indicated that combination of polymer retards the drug release in gastric region and releases ≥95% of drug in colonic region after ≥7 h. Whereas in case of in-vivo placebo x-ray imaging study had shown that the tablet reaches colonic part after 5±0.5 h providing the proof of arrival in the colon. Stability study indicated that the optimized formulation were physically and chemically stable.
  
  
  CONCLUSIONS
  Present research work concluded that compression coating by Eudragit RS 100 and HPMC K100 to 6-MP core provides potential colon targeted system with advantages of reduced gastric exposure and enhanced bioavailability. Formulation can be considered as potential and promising candidate for the treatment of colon diseases.
authors.forename: Rahul U
authors.initials: RU
authors.lastname: Hude
authors.affiliation: Department of Pharmaceutics, MAEER's Maharashtra Institute of Pharmacy, MIT Campus, Pune, (MS), 411038, India. jagdaleswati@rediffmail.com.
authors.forename: Swati C
authors.initials: SC
authors.lastname: Jagdale
mesh_terms: D002152:Calorimetry, Differential Scanning; D002626:Chemistry, Pharmaceutical; D003108:Colonic Diseases / Q000188:drug therapy*; D006801:Humans; D015122:Mercaptopurine / Q000008:administration & dosage / Q000627:therapeutic use*; D013056:Spectrophotometry, Ultraviolet; D017550:Spectroscopy, Fourier Transform Infrared; D013607:Tablets; D013996:Time and Motion Studies
chemical_list: D013607:Tablets; D015122:Mercaptopurine